CBD Isolate for Epilepsy
Purified, THC-free cannabidiol in crystalline form; shares CBD Oil's proposed anxiety-relieving and anti-inflammatory mechanisms without whole-plant entourage compounds, psychoactive effects, or most legal restrictions.
The connection
Neurological disorder characterised by recurrent seizures. Some cannabinoids have established anti-seizure efficacy for specific syndromes.
Also known as: Pure CBD, Cannabidiol isolate, Crystalline CBD
CBD Isolate × Epilepsy: at a glance
Every published result for this pair, extracted and audited.
CBD Isolate / Epilepsy: publication years
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Publications (count) |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2025 | 1 |
| 2026 | 2 |
CBD Isolate × Epilepsy: the evidence base
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Cannabidiol Use in Developmental and Epileptic Encephalopathies: A Syndrome- and Age-Stratified Systematic Review and Meta-analysisde Oliveira HM, et al. · CNS drugs · 2026PMID 42185726 ↗02Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-AnalysisRaminelli AO, et al. · Cannabis and cannabinoid research · 2025PMID 40956670 ↗03Medicinal cannabis for psychiatric disorders: a clinically-focused systematic reviewSarris J, et al. · BMC psychiatry · 2020PMID 31948424 ↗04Biological effects of Cannabidiol on normal human healthy cell populations: Systematic review of the literaturePagano S, et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020PMID 33038581 ↗05Aplicaciones terapéuticas por acción de los cannabinoidesPlancarte-Sánchez R, et al. · Gaceta medica de Mexico · 2019PMID 31219471 ↗06Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru(®), vs an Oil-Based Formulation, Epidyolex(®), Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I StudyBendik I, et al. · CNS drugs · 2026PMID 41888503 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.